Perioperative Tranexamic Acid Should Be Considered for Total Joint Arthroplasty Patients Receiving Apixaban for Thromboprophylaxis
Background: This study aims to investigate if the perioperative administration of tranexamic acid (TXA) for total joint arthroplasty (TJA) patients receiving apixaban for thromboprophylaxis can reduce the risk of postoperative bleeding without increasing the rate of thromboembolic events. Methods: T...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Arthroplasty Today |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352344124002334 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850053886052663296 |
|---|---|
| author | Sagar Telang, BS Ryan Palmer, BS Andrew Dobitsch, MD Jacob R. Ball, MD Nathanael D. Heckmann, MD Jay R. Lieberman, MD |
| author_facet | Sagar Telang, BS Ryan Palmer, BS Andrew Dobitsch, MD Jacob R. Ball, MD Nathanael D. Heckmann, MD Jay R. Lieberman, MD |
| author_sort | Sagar Telang, BS |
| collection | DOAJ |
| description | Background: This study aims to investigate if the perioperative administration of tranexamic acid (TXA) for total joint arthroplasty (TJA) patients receiving apixaban for thromboprophylaxis can reduce the risk of postoperative bleeding without increasing the rate of thromboembolic events. Methods: The Premier Healthcare Database was utilized to identify all primary elective total knee arthroplasty (TKA) and total hip arthroplasty (THA) patients. Patients receiving apixaban during their in-hospital admission who received TXA on the day of surgery were compared to those who did not receive TXA. Differences in demographics, hospital characteristics, and comorbidities were assessed between groups. Univariate and multivariable regressions were utilized to assess differences in 90-day bleeding, thromboembolic, and medical postoperative outcomes between cohorts. Results: In total, 118,219 TJA patients were identified (TKA: 65.3%; THA: 34.7%), of which 30,592 (25.9%) received apixaban alone, and 87,627 (74.1%) received apixaban and TXA. Multivariable analyses found that patients who received apixaban and TXA had a reduced risk of aggregate bleeding complications (adjusted odds ratio [aOR] 0.83, 95% confidence interval [CI]: 0.81-0.86, P < .001), transfusion (aOR 0.47, 95% CI: 0.43-0.52, P < .001), acute anemia (aOR 0.84, 95% CI: 0.81-0.87, P < .001), deep vein thrombosis (aOR 0.74, 95% CI: 0.66-0.83, P < .001), and pulmonary embolism (aOR 0.84, 95% CI: 0.72-0.96, P = .012). No differences between cohorts were observed for risk of stroke (aOR 1.09, 95% CI: 0.82-1.46, P = .372) and myocardial infarction (aOR 0.94, 95% CI: 0.76-1.16, P = .564). Conclusions: Perioperative administration of TXA to TJA patients receiving apixaban reduces the risk of bleeding complications without increasing thromboembolic risk. Arthroplasty surgeons should strongly consider providing TXA to TJA patients receiving apixaban. |
| format | Article |
| id | doaj-art-fd53fc76551f42e5847fbdddb244b41b |
| institution | DOAJ |
| issn | 2352-3441 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Arthroplasty Today |
| spelling | doaj-art-fd53fc76551f42e5847fbdddb244b41b2025-08-20T02:52:25ZengElsevierArthroplasty Today2352-34412024-12-013010154810.1016/j.artd.2024.101548Perioperative Tranexamic Acid Should Be Considered for Total Joint Arthroplasty Patients Receiving Apixaban for ThromboprophylaxisSagar Telang, BS0Ryan Palmer, BS1Andrew Dobitsch, MD2Jacob R. Ball, MD3Nathanael D. Heckmann, MD4Jay R. Lieberman, MD5Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USADepartment of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USADepartment of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USADepartment of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USACorresponding author. Keck Medical Center of USC, Department of Orthopaedic Surgery, 1520 San Pablo Street, Ste 2000, Los Angeles, CA 90333, USA. Tel.: +1 323 704 6363.; Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USADepartment of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USABackground: This study aims to investigate if the perioperative administration of tranexamic acid (TXA) for total joint arthroplasty (TJA) patients receiving apixaban for thromboprophylaxis can reduce the risk of postoperative bleeding without increasing the rate of thromboembolic events. Methods: The Premier Healthcare Database was utilized to identify all primary elective total knee arthroplasty (TKA) and total hip arthroplasty (THA) patients. Patients receiving apixaban during their in-hospital admission who received TXA on the day of surgery were compared to those who did not receive TXA. Differences in demographics, hospital characteristics, and comorbidities were assessed between groups. Univariate and multivariable regressions were utilized to assess differences in 90-day bleeding, thromboembolic, and medical postoperative outcomes between cohorts. Results: In total, 118,219 TJA patients were identified (TKA: 65.3%; THA: 34.7%), of which 30,592 (25.9%) received apixaban alone, and 87,627 (74.1%) received apixaban and TXA. Multivariable analyses found that patients who received apixaban and TXA had a reduced risk of aggregate bleeding complications (adjusted odds ratio [aOR] 0.83, 95% confidence interval [CI]: 0.81-0.86, P < .001), transfusion (aOR 0.47, 95% CI: 0.43-0.52, P < .001), acute anemia (aOR 0.84, 95% CI: 0.81-0.87, P < .001), deep vein thrombosis (aOR 0.74, 95% CI: 0.66-0.83, P < .001), and pulmonary embolism (aOR 0.84, 95% CI: 0.72-0.96, P = .012). No differences between cohorts were observed for risk of stroke (aOR 1.09, 95% CI: 0.82-1.46, P = .372) and myocardial infarction (aOR 0.94, 95% CI: 0.76-1.16, P = .564). Conclusions: Perioperative administration of TXA to TJA patients receiving apixaban reduces the risk of bleeding complications without increasing thromboembolic risk. Arthroplasty surgeons should strongly consider providing TXA to TJA patients receiving apixaban.http://www.sciencedirect.com/science/article/pii/S2352344124002334Total joint arthroplastyTranexamic acidApixabanTransfusionDeep vein thrombosisPulmonary embolism |
| spellingShingle | Sagar Telang, BS Ryan Palmer, BS Andrew Dobitsch, MD Jacob R. Ball, MD Nathanael D. Heckmann, MD Jay R. Lieberman, MD Perioperative Tranexamic Acid Should Be Considered for Total Joint Arthroplasty Patients Receiving Apixaban for Thromboprophylaxis Arthroplasty Today Total joint arthroplasty Tranexamic acid Apixaban Transfusion Deep vein thrombosis Pulmonary embolism |
| title | Perioperative Tranexamic Acid Should Be Considered for Total Joint Arthroplasty Patients Receiving Apixaban for Thromboprophylaxis |
| title_full | Perioperative Tranexamic Acid Should Be Considered for Total Joint Arthroplasty Patients Receiving Apixaban for Thromboprophylaxis |
| title_fullStr | Perioperative Tranexamic Acid Should Be Considered for Total Joint Arthroplasty Patients Receiving Apixaban for Thromboprophylaxis |
| title_full_unstemmed | Perioperative Tranexamic Acid Should Be Considered for Total Joint Arthroplasty Patients Receiving Apixaban for Thromboprophylaxis |
| title_short | Perioperative Tranexamic Acid Should Be Considered for Total Joint Arthroplasty Patients Receiving Apixaban for Thromboprophylaxis |
| title_sort | perioperative tranexamic acid should be considered for total joint arthroplasty patients receiving apixaban for thromboprophylaxis |
| topic | Total joint arthroplasty Tranexamic acid Apixaban Transfusion Deep vein thrombosis Pulmonary embolism |
| url | http://www.sciencedirect.com/science/article/pii/S2352344124002334 |
| work_keys_str_mv | AT sagartelangbs perioperativetranexamicacidshouldbeconsideredfortotaljointarthroplastypatientsreceivingapixabanforthromboprophylaxis AT ryanpalmerbs perioperativetranexamicacidshouldbeconsideredfortotaljointarthroplastypatientsreceivingapixabanforthromboprophylaxis AT andrewdobitschmd perioperativetranexamicacidshouldbeconsideredfortotaljointarthroplastypatientsreceivingapixabanforthromboprophylaxis AT jacobrballmd perioperativetranexamicacidshouldbeconsideredfortotaljointarthroplastypatientsreceivingapixabanforthromboprophylaxis AT nathanaeldheckmannmd perioperativetranexamicacidshouldbeconsideredfortotaljointarthroplastypatientsreceivingapixabanforthromboprophylaxis AT jayrliebermanmd perioperativetranexamicacidshouldbeconsideredfortotaljointarthroplastypatientsreceivingapixabanforthromboprophylaxis |